---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086127"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:40:27.472564+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials

## Summary
- Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.
- R&D spend $2.9M (-33% YoY); G&A $1.7M (+13%); interest income $0.2M.
- NXP800 Phase 1b ovarian cancer trial enrolling at ~15 US/UK sites; update due fall 2024.
- NXP800 investigator-sponsored cholangiocarcinoma trial recruiting; update expected by end of 2024.
- NXP900 dose escalation: 3 cohorts complete, no DLTs; planning combo with EGFR/ALK inhibitors in NSCLC.

## SEC filing metadata
- accession: 0001104659-24-086127
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465924086127/0001104659-24-086127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465924086127/tm2420911d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086127
- JSON: https://secwatch.observer/filing/0001104659-24-086127.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.